Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy group - Appoints Frank Mathias as chief executive officer and board director, effective March 2023.
Mathias joins from Rentschler Biopharma SE, where he has served as CEO since 2016. Roch Doliveux will remain as interim CEO until March 2023, at which point Mathias will fully take over the role and Doliveux will become a non-executive chair.
Outgoing CEO Doliveux says: "Frank is an outstanding patient centric leader with impressive experience from a top-end CDMO as well as from innovative biopharma companies. He has a strong track record of delivering growth and driving performance and innovation which are core strengths required to implement our strategy of becoming an innovative global viral vector leader."
Current stock price: 357.38 pence, down 1.4% on Tuesday
12-month change: down 75%
By Holly Beveridge; hollybeveridge@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)